(Q44963037)

7 December 2017

title

Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease (English)

1 reference

7 December 2017

0 references

1 reference

9

Robert M Califf

1 reference

7 December 2017

4

Donal Reddan

1 reference

7 December 2017

Peter A McCullough

1

1 reference

7 December 2017

Huiman X Barnhart

2

1 reference

7 December 2017

Jula K Inrig

3

1 reference

7 December 2017

Shelly Sapp

5

1 reference

7 December 2017

Uptal D Patel

6

1 reference

7 December 2017

Ajay K Singh

7

1 reference

7 December 2017

Lynda A Szczech

8

1 reference

7 December 2017

publication date

25 May 2013

1 reference

American Journal of Nephrology

7 December 2017

published in

1 reference

7 December 2017

volume

37

1 reference

7 December 2017

issue

6

1 reference

7 December 2017

page(s)

549-558

1 reference

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

7 December 2017

cites work

1 reference

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

21 January 2018

1 reference

Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.

21 January 2018

1 reference

A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment

21 January 2018

1 reference

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study

21 January 2018

1 reference

An expert opinion on the current treatment of anemia in patients with kidney disease

21 January 2018

1 reference

Hyporesponsiveness to erythropoietin: causes and management

21 January 2018

1 reference

Factors predicting erythropoietin resistance among maintenance hemodialysis patients.

21 January 2018

1 reference

Increased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin

21 January 2018

1 reference

Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy

21 January 2018

1 reference

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

21 January 2018

1 reference

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

21 January 2018

1 reference

Trends in anemia management among US hemodialysis patients

21 January 2018

1 reference

Epoetin requirements predict mortality in hemodialysis patients

21 January 2018

1 reference

Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis

21 January 2018

1 reference

Erythropoietin receptor mRNA expression in human endothelial cells

21 January 2018

1 reference

Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

21 January 2018

1 reference

Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma.

21 January 2018

1 reference

The new FDA labeling for ESA--implications for patients and providers

21 January 2018

1 reference

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

21 January 2018

1 reference

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000351175

1 reference

7 December 2017

1 reference